Aggarwal Ajay 4

What Happened
Ajay Aggarwal, Chief Operating Officer of Cardiff Oncology (CRDF), was granted 400,000 derivative shares on April 27, 2026 (reported as an "A" — award/grant). The grant is reported at $0.00 per share (no cash paid) and therefore shows $0 total purchase value in the filing. This is a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: April 27, 2026; Form 4 filed April 28, 2026 (timely filing).
• Transaction type/code: A — Award/Grant (derivative).
• Shares granted: 400,000; Price per share: $0.00 (reported as derivative award).
• Shares owned after transaction: not specified in the filing.
• Vesting (footnote): 100,000 vest on April 27, 2027; then 8,333 shares vest monthly for 36 months beginning May 27, 2027.
• Filing timeliness: filed the next day (no late-filing indication).

Context
Derivative awards like this are typically restricted stock units or similar compensation and are subject to the vesting schedule above; they do not represent an immediate market purchase or sale. For retail investors, grants signal executive compensation/retention but are not direct indicators of the insider buying or selling stock on the open market.